GATT Technologies (BV, Nijmegen, The Netherlands) is a privately owned, clinical-stage, medical device company. GATT has developed a synthetic platform leveraging an activated polymer technology that aims to become the next frontier in managing complex bleeding and sealing. GATT’s hemostats and sealants focus on controlling severe and/or problematic surgical bleedings as well as preventing and treating organ leakages. GATT’s solutions have the potential to become a superior alternative to the current fibrin and PEG-polymer based solutions in terms of speed, efficacy and cost.
The current focus of the company is to conduct its first clinical trial in Europe for its lead product – GATT-Patch – a fast hemostatic sealing patch. Following the European trial, additional trials will be executed – in the US, to target FDA approval, as well as to expand its target indications such as soft tissue, cardiovascular, lung, kidney and pancreas. Additionally, the company is advancing its other products including GATT-Powder (targeted for use on large surfaces and hard to access areas) and GATT-Gel (targeted for high pressure vessel sealing).